REG - Hemogenyx Pharma Plc - CBR Brain Delivery

Hemogenyx PharmaceuticalsAnnouncement

16/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240216:nRSP3442Da&default-theme=true

RNS Number : 3442D  Hemogenyx Pharmaceuticals PLC  16 February 2024

16 February 2024

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

CBR Brain Delivery

 

Chimeric Bait Receptors for Combatting Brain Cancers and Neurodegenerative
Diseases Can Be Delivered via Programmed Microglial Cells

 

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage
biopharmaceutical group, announces that it has demonstrated in vivo that its
proprietary Chimeric Bait Receptor ("CBR") can be delivered into the brain via
programmed microglial cells for the potential treatment of brain cancers and
certain neurodegenerative diseases.

Delivery of therapeutics across the blood-brain barrier is one of the most
difficult problems in the treatment of brain cancers and certain
neurodegenerative diseases. Our scientists at have developed a method of
transplantation of human hematopoietic (blood) stem cells ("HSC") that allows
their engraftment and differentiation into microglial cells (immune cells that
reside in the brain) in the brains of immune-compromised mice.

 

The Company believes that autologous HSCs that are genetically modified to
make CBR and transplanted back to a patient could give rise to microglial
cells in the patient's brain. Such microglial cells that have been armed with
CBR could potentially be able to find and phagocytose (ingest and destroy)
either brain cancer cells or abnormal protein aggregations (e.g., amyloid
plaques in Alzheimer's).

 

The Company's approach described above may offer a number of benefits: (1) it
could deliver CBR therapeutics across the blood brain barrier; (2) CBR-armed
microglial cells may not be rejected as they are
autologous/patient-derived; (3) CBR-armed microglial cells may provide
long-term protection of the brain against cancer or protein aggregations
because microglial cells live for a long time;  and (4) autologous HSC,
which are self-renewing, could become an almost unlimited source of CBR-armed
microglial cells for the patient.

 

This is a further indication of the growing range and versatility of CBR as a
potential tool against a variety of difficult to treat and deadly conditions.

 

Research continues on CBR and the Company intends to increase its focus on
this once HEMO-CAR-T has entered clinical trials.

 

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented: "This major breakthrough in the method of delivery of our CBR into
the brain is a unique tool that may allow us to successfully tackle some of
the most difficult and often incurable human diseases. As we broaden the scope
of use for our CBR platform, we are eager to continue its development."

 

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement.

 

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)

 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl

 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments for life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as a platform technology that it uses as an engine for
novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RESGPUMCPUPCGQA